Preparation and evaluation of a timolol maleate drug–resin ophthalmic suspension as a sustained-release formulation in vitro and in vivo

References

• Huber M, Koelzsch M, Stahlmann R, et al. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma. Drugs Aging 2013;30:31–8
   PubMed Web of Science ®Google Scholar
• Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advance in ocular drug delivery. Drug Dev Ind Pharm 2013;39:1599–617
   PubMed Web of Science ®Google Scholar
• Fukuda M, Sasaki H. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes. J Ocul Pharmacol Ther 2015;31:57–60
   PubMed Web of Science ®Google Scholar
• Pathak MK, Chhabra G, Pathak K. Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex vivo transcorneal permeation, corneal toxicity and irritation testing. Drug Dev Ind Pharm 2013;39:780–90
   PubMed Web of Science ®Google Scholar
• Yu S, Wang Q-M, Wang X, et al. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm 2015;480:128–36
   PubMed Web of Science ®Google Scholar
• Tashakori-Sabzevar F, Mohajeri SA. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses. Drug Dev Ind Pharm 2015;41:703–13
   PubMed Web of Science ®Google Scholar
• Achouri D, Sergent M, Tonetto A, et al. Self-assembled liquid crystalline nanoparticles as an ophthalmic drug delivery system. Part II: optimization of formulation variables using experimental design. Drug Dev Ind Pharm 2015;41:493–501
   PubMed Web of Science ®Google Scholar
• Knight ORJ, Lawrence SD. Sustained drug delivery in glaucoma. Curr Opin Ophthalmol 2014;25:112–17
   PubMed Web of Science ®Google Scholar
• Hodges RR, Dartt DA. Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins. Exp Eye Res 2013;117:62–78
   PubMed Web of Science ®Google Scholar
• Maenpaa J, Volotinen-Maja M, Kautiainen H, et al. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. Drug Metab Dispos 2014;42:2068–76
   PubMed Web of Science ®Google Scholar
• Samprasit W, Rojanarata T, Akkaramongkolporn P, et al. Improvement of drug loading onto ion exchange resin by cyclodextrin inclusion complex. Drug Dev Ind Pharm 2013;39:1672–80
   PubMed Web of Science ®Google Scholar
• Jumde AB, Umekar MJ, Kotagale NR. Complexation using direct current: novel batch method for drug-resinate preparation. Drug Dev Ind Pharm 2013;39:978–84
   PubMed Web of Science ®Google Scholar
• Samprasit W, Akkaramongkolporn P, Ngawhirunpat T, et al. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins. Drug Dev Ind Pharm 2015;41:1006–16
   PubMed Web of Science ®Google Scholar
• Garekani HA, Nokhodchi A, Rayeni MA, Sadeghi F. Preparation and characterization and release properties of Eudragit RS based ibuprofen pellets prepared by extrusion spheronization: effect of binder type and concentration. Drug Dev Ind Pharm 2013;39:1238–46
   PubMed Web of Science ®Google Scholar
• Sun C, Liu H, Zhao X, et al. In vitro and in vivo evaluation of a novel diltiazem hydrochloride polydispersity sustained-release system. Drug Dev Ind Pharm 2013;39:62–6
   PubMed Web of Science ®Google Scholar
• Li J, Liu H, Liu L-L, et al. Design and evaluation of a brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery. Chem Pharm Bull 2014;62:1000–8
   PubMed Web of Science ®Google Scholar
• Singh J, Chhabra G, Pathak K. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro, ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm 2014;40:1223–32
   PubMed Web of Science ®Google Scholar
• Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm 2010;396:179–87
   PubMed Web of Science ®Google Scholar
• Yao W, Sun K, Mu H, et al. Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system. Drug Dev Ind Pharm 2010;36:1027–35
   PubMed Web of Science ®Google Scholar
• Senthilkumari S, Velpandian T, Biswas NR, et al. Evaluation of the modulation of P-glycoprotein (P-gp) on the intraocular disposition of its substrate in rabbits. Curr Eye Res 2008;33:333–43
   PubMed Web of Science ®Google Scholar
• Gao Y, Sun Y, Ren F, Gao S. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate. Drug Dev Ind Pharm 2010;36:1131–8
   PubMed Web of Science ®Google Scholar
• Genta I, Conti B, Perugini P, et al. Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol 1997;49:737–42
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhai J-J, Chen J-Q, et al. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J Ocul Pharmacol Ther 2009;25:345–50
   PubMed Web of Science ®Google Scholar
• Jani R, Gan O, Ali Y, et al. Ion exchange resins for ophthalmic delivery. J Ocul Pharmacol Ther 1994;10:57–67
   Web of Science ®Google Scholar
• Liu R, Liu Z, Zhang C, Zhang B. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J Pharm Sci 2012;101:3833–44
   PubMed Web of Science ®Google Scholar
• Jain SP, Shah SP, Rajadhyaksha NS, et al. In situ ophthalmic get of ciprofloxacin hydrochloride for once a day sustained delivery. Drug Dev Ind Pharm 2008;34:445–52
   PubMed Web of Science ®Google Scholar
• Hornof MD, Bernkop-Schnrch A. In vitro evaluation of the permeation enhancing effect of polycarbophil–cysteine conjugates on the cornea of rabbits. J Pharm Sci 2002;91:2588–92
   PubMed Web of Science ®Google Scholar
• Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005;102:23–38
   PubMed Web of Science ®Google Scholar
• Jain GK, Pathan SA, Akhter S, et al. Microscopic and spectroscopic evaluation of novel PLGA–chitosan nanoplexes as an ocular delivery system. Colloids Surf B: Biointerfaces 2011;82:397–403
   PubMed Web of Science ®Google Scholar
• Shen J, Deng Y, Jin X, et al. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 2010;402:248–53
   PubMed Web of Science ®Google Scholar
• Volotinen M, Maenpaa J, Kautiainen H, et al. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor. Eur J Pharm Sci 2009;36:292–6
   PubMed Web of Science ®Google Scholar
• Volotinen M, Hakkola J, Pelkonen O, et al. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol 2011;108:297–303
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Nino J, Tahvanainen K, et al. Efficacy and systemic side effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand 2005;83:723–8
   PubMedGoogle Scholar